Lantern Pharma (LTRN) Competitors

Y-mAbs Therapeutics (NASDAQ:YMAB) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Do insiders and institutionals hold more shares of YMAB or LTRN?

70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are owned by institutional investors. 19.7% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Lantern Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more risk and volatility, YMAB or LTRN?

Y-mAbs Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Does the media favor YMAB or LTRN?

In the previous week, Y-mAbs Therapeutics had 21 more articles in the media than Lantern Pharma. MarketBeat recorded 26 mentions for Y-mAbs Therapeutics and 5 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.71 beat Y-mAbs Therapeutics' score of 0.06 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Y-mAbs Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantern Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, YMAB or LTRN?

Lantern Pharma has lower revenue, but higher earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	$87.68M	4.40	-$29.67M	-$0.50	-17.03
Lantern Pharma	N/A	N/A	-$20.78M	-$1.84	-2.42

Is YMAB or LTRN more profitable?

Lantern Pharma has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.34% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	-26.03%	-24.34%	-18.86%
Lantern Pharma	N/A	-83.26%	-70.65%

Do analysts prefer YMAB or LTRN?

Y-mAbs Therapeutics presently has a consensus price target of $11.16, suggesting a potential upside of 31.06%. Lantern Pharma has a consensus price target of $25.00, suggesting a potential upside of 461.80%. Given Lantern Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Lantern Pharma is more favorable than Y-mAbs Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	2 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.08
Lantern Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Y-mAbs Therapeutics beats Lantern Pharma on 8 of the 15 factors compared between the two stocks.